A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key ...

The District Court for the District of Delaware recently rejected Novartis’s effort to block MSN Pharmaceuticals from launching a generic version ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

During its latest earnings call, Novartis said it currently expects Entresto generics to hit in mid-2025, though the company is defending against that possibility on multiple patent fronts in a ...

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...

Cigna Corp.CI0.76%increase; green up pointing triangle and Aetna Inc. have reached agreements for heart drug Entresto with Swiss drugmaker Novartis AG that tie pricing to patient outcomes. Such ...

Novartis Entresto® granted expanded indication in chronic heart failure by FDA Published. Feb 16, 2021 1:22PM EST. Entresto is the first and only therapy approved in the US to treat patients ...